Evidence map›Paper›PMID 40366517›Full record

ArticleHead and neck pathology2025

Clinicopathologic and Molecular Characterization of SMARCB1-Deificient Sinonasal Carcinomas -A Systematic Study from a Single Institution Cohort.

Qinyuan Li, Tarek Abi-Saab, Andrey Prilutskiy, Vanessa Horner, Leah Frater-Rubsam, Yajing Peng, Wei Huang, Randall J Kimple, Paul M Harari, Ricardo V Lloyd and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Head and neck pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Clinical, genetic and immunohistochemical characterization of sinonasal tumors with neuroectodermal differentiation.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qinyuan LiDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Tarek Abi-SaabDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Andrey PrilutskiyDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Vanessa HornerDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Leah Frater-RubsamWisconsin State Laboratory of Hygiene, Madison, WI, 53706, USA.
Yajing PengWisconsin State Laboratory of Hygiene, Madison, WI, 53706, USA.
Wei HuangDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Randall J KimpleDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Paul M HarariDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Ricardo V LloydDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Rong HuDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, 53705, USA. rhu6@wisc.edu.

Funding

Project 3: Modulation of the head and neck tumor immune microenvironment by targeting the TAM family of receptorsP50CA278595 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI David J Beebe · 2022 to 2026
$12.5M
NCI NIH HHS P50 CA278595NIH HHS P50 CA278595
6 · The paper itself

Abstract

backgroundSMARCB1-deficient and SMARCA4-deficient sinonasal carcinomas are rare, with only a few systematic studies available in the literature. Secondary EWSR1 gene abnormalities have been reported in SMARCB1-deficient tumors. This study aimed to systematically investigate SWI/SNF complex-deficient sinonasal carcinomas in a single-institution cohort, perform clinicopathologic characterization, and explore the underlying molecular mechanisms.

methodImmunohistochemistry (IHC) of INI1 and BRG1 was performed on tissue microarrays containing tumor tissue from 149 consecutive sinonasal carcinomas. Single nucleotide polymorphism (SNP) array and EWSR1 gene fluorescence in situ hybridization (FISH) analyses were conducted on SMARCB1-deficient sinonasal carcinomas. Clinicopathologic characterization was studied.

resultOf the 149 sinonasal carcinomas, 7 (4.7%) showed SMARCB1 loss, while none demonstrated SMARCA4 loss. All patients were male and presented with advanced-stage tumors. Four SMARCB1-deficient sinonasal carcinomas exhibited basaloid morphology, two displayed eosinophilic tumor morphology, and one had mixed morphology. Homozygous and heterozygous SMARCB1 deletions were identified in 4/6 and 2/6 cases respectively. Heterozygous loss involving genes neighboring SMARCB1 gene, including EWSR1, was observed in four cases. One tumor showed a heterozygous loss of the entire chromosome 22q. EWSR1 FISH assay revealed concordant heterozygous EWSR1 loss in these five cases.

conclusionSMARCB1-deficient carcinomas account for 4.7% of sinonasal carcinomas in this single-institution cohort, while SMARCA4-deficient tumors are even rarer, with none identified. SMARCB1-deficient sinonasal carcinomas exhibit a broad spectrum of morphologic and immunohistochemical features. These carcinomas show complex genetic alterations, with homozygous SMARCB1 deletions present in the majority of cases.

Indexed as

Biomarkers, TumorCarcinomaParanasal Sinus NeoplasmsSMARCB1 ProteinAdultAgedAged, 80 and overCohort StudiesDNA HelicasesFemaleHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMaleMiddle AgedNuclear ProteinsBiomarkers, TumorDNA HelicasesEWSR1 protein, humanNuclear ProteinsRNA-Binding Protein EWSSMARCA4 protein, humanSMARCB1 ProteinSMARCB1 protein, humanTranscription FactorsEWSR1Sinonasal carcinomaSMARCA4SMARCB1SWI/SNF complex

Identifiers

PMID40366517
PMCPMC12078905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.